PHIO - צמיחת מכירות משנה לשנה (TTM) Phio Pharmaceuticals

Phio Pharmaceuticals is advancing the fight against cancer through RNA interference, as confirmed by the TTM annual revenue dynamics. The strategy is based on creating targeted therapies to block immune-suppressor genes. The technological moat is provided by a unique system for local tumor targeting. Meanwhile, 0.00 serves as the final level marker, capturing the current state of business expansion within the genetic engineering sector.
Phio Pharmaceuticals Corp. - פילוחים אנליטיים ומדדי מפתח (PHIO)

The market values Phio Pharmaceuticals (PHIO) through the lens of its innovative RNA therapy pipeline's efficiency. This metric measures the percentage change in revenue over the last 12 months relative to the preceding period. By analyzing the current TTM year-over-year revenue growth rate, an investor determines the pace of the business's commercial expansion. The diversification of in vivo preclinical testing stages directly impacts the dynamics of this indicator. A steady upward trend confirms the resilience of the biotech startup's financial model.